Crispr Therapeutics AG vs PayPal Holdings, Inc. — how do they compare? Crispr Therapeutics AG trades at $50.95 (market cap $5.06B), while PayPal Holdings, Inc. trades at $55.07 (market cap $47.01B). The key difference: PayPal Holdings, Inc. is far larger — about 9.3× Crispr Therapeutics AG's market cap, and PayPal Holdings, Inc. pays a 1.02% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and PayPal Holdings, Inc. for 106 Days on average.
| CRSP | PYPL | |
|---|---|---|
Market Cap | $5.06B | $47.01B |
Volume | 1,678,371 | 10,493,459 |
Sector | Health | Financials |
52-Week High | $74.92 | $75.75 |
52-Week Low | $44.34 | $39.08 |
Typical Hold Time | 77 Days | 106 Days |
Enterprise Value | $3.48B | $49.15B |
Dividend Yield | — | 1.02% |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 6.59% over 24 hours amid bearish technical signals. The company shows negative profitability metrics with -4,101.26% net income margin and -$581.60M net loss for 2025, though Q2 2026 EPS beat expectations. Recent news highlights upcoming clinical data presentations and commercial progress with CASGEVY gene therapy. Cash flow remains negative from operations but positive overall due to financing activities.
While analyst consensus remains bullish with 57.9% buy ratings and $67.83 price target, significant execution risks persist. The stock faces pressure from sustained cash burn and competitive threats, but potential catalysts include upcoming clinical data readouts and CASGEVY revenue growth. Investors should weigh high-risk biotech volatility against breakthrough therapy potential.
PayPal (PYPL) trades at $54.95, up 0.62% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $56.47. The stock shows strong profitability with a net income margin of 14.36% and ROE of 24.5%, supported by recent earnings beats in Q1 and Q2 2026. A new partnership with Meta's AI agent for checkout services, announced on September 22, 2026, provides a potential growth catalyst amid competitive pressures in digital payments.
PYPL presents a value opportunity with a low P/E of 10.39 and solid cash flow, but faces risks from slowing branded checkout growth and intense fintech competition. The stock's upside hinges on successful execution of Venmo expansion and cost-cutting initiatives under new CEO Enrique Lores, with investor sentiment cautiously optimistic given the 35.71% buy rating from analysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →